Emerging immunotherapies in ovarian cancer

Laureen S. Ojalvo, Paige E. Nichols, Danijela Jelovac, Leisha A. Emens

Research output: Contribution to journalArticlepeer-review

Abstract

Despite a global effort to significantly reduce mortality, ovarian cancer remains the fifth leading cause of cancer death among American women, and five-year survival rates remain discouragingly low at 45%. Novel therapies are urgently needed. Notably, higher infiltration of activated immune cells into the tumor microenvironment correlates with improved ovarian cancer survival, suggesting that promoting their activity could favorably impact clinical outcomes. Immunotherapy has recently demonstrated impressive clinical benefit in a variety of solid tumors. Immunotherapy strategies tested in ovarian cancer include vaccines, adoptive T cell therapy and immune checkpoint blockade. Ultimately, a combination immunotherapy approach that integrates immunotherapy with other cancer treatment modalities in additive or synergistic ways will most effectively improve survival.

Original languageEnglish (US)
Pages (from-to)97-109
Number of pages13
JournalDiscovery Medicine
Volume20
Issue number109
StatePublished - 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Emerging immunotherapies in ovarian cancer'. Together they form a unique fingerprint.

Cite this